Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,610 Million (Small Cap)
58.00
NA
0.50%
-0.62
5.93%
3.42
Revenue and Profits:
Net Sales:
160 Million
(Quarterly Results - Jun 2025)
Net Profit:
19 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.01%
0%
-4.01%
6 Months
49.18%
0%
49.18%
1 Year
51.16%
0%
51.16%
2 Years
44.44%
0%
44.44%
3 Years
55.57%
0%
55.57%
4 Years
86.36%
0%
86.36%
5 Years
60.94%
0%
60.94%
Tibet Aim Pharm., Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.20%
EBIT Growth (5y)
20.84%
EBIT to Interest (avg)
24.78
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.60
Sales to Capital Employed (avg)
0.89
Tax Ratio
21.41%
Dividend Payout Ratio
40.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.70%
ROE (avg)
6.15%
Valuation key factors
Factor
Value
P/E Ratio
58
Industry P/E
Price to Book Value
3.42
EV to EBIT
46.85
EV to EBITDA
32.18
EV to Capital Employed
7.30
EV to Sales
3.57
PEG Ratio
NA
Dividend Yield
0.50%
ROCE (Latest)
15.58%
ROE (Latest)
5.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
160.00
188.50
-15.12%
Operating Profit (PBDIT) excl Other Income
28.30
17.90
58.10%
Interest
0.30
0.10
200.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
18.80
11.90
57.98%
Operating Profit Margin (Excl OI)
145.00%
65.60%
7.94%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -15.12% vs -6.17% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 57.98% vs 91.94% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
639.60
655.50
-2.43%
Operating Profit (PBDIT) excl Other Income
49.50
52.00
-4.81%
Interest
0.50
1.20
-58.33%
Exceptional Items
-0.70
-19.80
96.46%
Consolidate Net Profit
47.50
15.70
202.55%
Operating Profit Margin (Excl OI)
43.40%
39.70%
0.37%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -2.43% vs -22.40% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 202.55% vs -65.94% in Dec 2023
About Tibet Aim Pharm., Inc. 
Tibet Aim Pharm., Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






